Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Peter Kim, Julie Goonewardene, Walter Capone

Premium

Peter Kim, former Merck Research Laboratories president, will return to his alma mater Stanford University as a professor of biochemistry at the School of Medicine.

On Feb. 1, Kim will take up his position at the school, where he earned his PhD in biochemistry in 1985. He will also be a member of the Stanford Institute of Chemical Biology, a new joint effort between the School of Medicine, the School Engineering, and the School of Humanities and Sciences.

Kim retired this year from Merck after more than a decade at the firm. He was replaced by Roger Perlmutter, former head of R&D at Amgen.


Personalized medicine-focused consulting firm Diaceutics has picked Julie Goonewardene to chair its board of advisors.

Goonewardene is currently president of KUIC and associate vice chancellor for innovation and entrepreneurship at the University of Kansas. She co-founded and was CEO of Cantilever Technologies, as well as past president of the Strategic Systems Group.


The Multiple Myeloma Research Foundation has promoted Walter Capone from chief operating officer to president, effective as of December 16. Capone will report directly to Kathy Giusti, MMRF founder and CEO. Before MMRF, Capone was VP of commercial development and operations at Progenics Pharmaceuticals.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.